-
公开(公告)号:US20240307440A1
公开(公告)日:2024-09-19
申请号:US18525271
申请日:2023-11-30
申请人: AUTOLUS LIMITED
发明人: Martin Pulé , Simon Thomas , Shaun Cordoba , Wen Chean Lim
IPC分类号: A61K35/17 , C07K14/475 , C07K14/725 , C12N5/0783 , C12N15/85
CPC分类号: A61K35/17 , C07K14/475 , C07K14/7051 , C12N5/0636 , C12N15/85 , C12N2510/00
摘要: The present invention provides a cell which comprises a first exogenous nucleic acid molecule encoding a Chimeric Antigen Receptor (CAR) and a second exogenous nucleic acid molecule encoding a transcription factor.
-
公开(公告)号:US11982672B2
公开(公告)日:2024-05-14
申请号:US17832162
申请日:2022-06-03
申请人: AUTOLUS LIMITED
发明人: Martin Pulé , Paul Maciocia
IPC分类号: G01N33/574 , C12Q1/6886 , G16H50/30 , A61K39/00 , C12Q1/686
CPC分类号: G01N33/57492 , C12Q1/6886 , G16H50/30 , A61K2039/515 , C12Q1/686
摘要: The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.
-
公开(公告)号:US11965173B2
公开(公告)日:2024-04-23
申请号:US16772216
申请日:2018-12-14
申请人: AUTOLUS LIMITED
CPC分类号: C12N15/86 , C12N15/85 , C12N2740/13022 , C12N2740/13043 , C12N2740/13052 , C12N2800/107
摘要: There is provided a plasmid system for transfection into a cell to create a producer cell, the system comprising: a. a helper plasmid comprising a first nucleotide sequence encoding Murine leukemia virus (MLV)-derived Gag and Pol poly-proteins; b. an envelope plasmid comprising a second nucleotide sequence encoding an Env protein; c. a genome plasmid comprising a third nucleotide sequence encoding a retroviral genome, wherein the first nucleotide sequence is codon-shuffled to remove any significant regions of homology with the third nucleotide sequence; and wherein the second nucleotide sequence is codon-optimised for expression in the producer cell.
-
公开(公告)号:US11885807B2
公开(公告)日:2024-01-30
申请号:US17832371
申请日:2022-06-03
申请人: AUTOLUS LIMITED
发明人: Martin Pulé , Paul Maciocia
IPC分类号: G01N33/574 , G16H50/30 , C12Q1/6886 , C12Q1/686 , A61K39/00
CPC分类号: G01N33/57492 , C12Q1/6886 , G16H50/30 , A61K2039/515 , C12Q1/686
摘要: The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TOR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.
-
公开(公告)号:US20230338534A1
公开(公告)日:2023-10-26
申请号:US17915737
申请日:2021-04-08
申请人: AUTOLUS LIMITED
发明人: Martin Pulé
IPC分类号: A61K39/00
CPC分类号: A61K39/4637 , A61K39/4631 , A61K39/46433 , A61K39/4644 , A61K39/46449 , A61K39/4611 , A61K39/464412 , A61K39/464411 , A61K39/4622 , A61K39/464463 , A61K2239/17 , A61K2239/11 , A61K2239/26 , A61K2239/57 , A61K2239/46
摘要: The present invention provides a method for treating a disease in a subject, which comprises the step of administering to the subject a plurality of cells which express: (a) a chimeric antigen receptor (CAR); and (b) a mutant version of calcineurin A and/or calcineurin B which is resistant to the calcineurin inhibitor. The subject may be receiving or have received treatment with a calcineurin inhibitor. The CAR-expressing cells may be administered prior to, following, simultaneously with or in combination with a calcineurin inhibitor.
-
公开(公告)号:US20230242937A1
公开(公告)日:2023-08-03
申请号:US16772216
申请日:2018-12-14
申请人: AUTOLUS LIMITED
CPC分类号: C12N15/86 , C12N15/85 , C12N2740/13052 , C12N2740/13022 , C12N2740/13043 , C12N2800/107
摘要: There is provided a plasmid system for transfection into a cell to create a producer cell, the system comprising: a. a helper plasmid comprising a first nucleotide sequence encoding Murine leukemia virus (MLV)-derived Gag and Pol poly-proteins; b. an envelope plasmid comprising a second nucleotide sequence encoding an Env protein; c. a genome plasmid comprising a third nucleotide sequence encoding a retroviral genome, wherein the first nucleotide sequence is codon-shuffled to remove any significant regions of homology with the third nucleotide sequence; and wherein the second nucleotide sequence is codon-optimised for expression in the producer cell.
-
公开(公告)号:US20230148144A1
公开(公告)日:2023-05-11
申请号:US17915802
申请日:2021-04-08
申请人: AUTOLUS LIMITED
发明人: Shaun Cordoba , Martin Pulé , Vania Baldan , Alex Nicholson
IPC分类号: A61K35/17 , C12N9/16 , C07K14/74 , C07K14/725 , C12N5/0783 , A61K31/436 , A61K38/17
CPC分类号: A61K35/17 , C12N9/16 , C12Y301/03016 , C07K14/70539 , C07K14/7051 , C12N5/0636 , A61K31/436 , A61K38/1774 , C07K2319/30 , C07K2319/03 , A61K2035/122
摘要: There is provided an effector immune cell which expresses a cell surface receptor or receptor complex which specifically binds an antigen recognition receptor of a target immune cell; which effector immune cell is engineered such that when a synapse is formed between the effector immune cell and the target immune cell, the capacity of the effector immune cell to kill the target immune cell is greater than the capacity of the target immune cell to kill the effector immune cell. There is also provided the use of such a cell in methods for treating cancer, preventing allograft rejection and GVHD.
-
公开(公告)号:US20230090553A1
公开(公告)日:2023-03-23
申请号:US17823003
申请日:2022-08-29
申请人: AUTOLUS LIMITED
发明人: Shaun Cordoba , Shimobi Onuoha , Alexander Kinna , Simon Thomas , Ram Jha , Martin Pulé
IPC分类号: C12N15/85 , A61K35/17 , C07K14/725 , C12N5/0783 , G01N33/50
摘要: The present invention relates to engineered a cytolytic immune cell comprising: i) a releasable protein which comprises a polypeptide of interest (POI) and a first interaction domain; and ii) a retention protein which is retained within an intracellular compartment of the cell and comprises a second interaction domain which binds to the first protein interaction domain, wherein binding between the first protein interaction domain and second protein interaction domain is disrupted by the presence of an agent, such that in the absence of the agent, the first protein interaction domain and second protein interaction domain bind and result in retention of the POI within an intracellular compartment; whereas in the presence of the agent, the first protein interaction domain and second protein interaction do not bind and the POI is released from the intracellular compartment and expressed at the cell surface or secreted by the cell.
-
公开(公告)号:US11530420B2
公开(公告)日:2022-12-20
申请号:US15568859
申请日:2016-04-26
申请人: AUTOLUS LIMITED
发明人: Martin Pulé , Shaun Cordoba
IPC分类号: C12N15/00 , C12N15/86 , C07K14/705 , C07K16/28 , C12N15/85
摘要: The present invention provides a nucleic acid construct comprising the following structure: A-X-B in which A and B are nucleic acid sequences encoding a first and a second polypeptide of interest (POI); and X is a nucleic acid sequence which encodes a cleavage site, wherein either the first or second POI is a transmembrane protein which comprises an intracellular retention signal.
-
公开(公告)号:US20220289820A1
公开(公告)日:2022-09-15
申请号:US17628509
申请日:2020-08-04
申请人: AUTOLUS LIMITED
发明人: Martin Pulé , Shaun Cordoba , Simon Thomas , Shimobi Onouha , Matteo Righi
IPC分类号: C07K14/735 , C07K14/715 , C07K16/30 , A61P35/00
摘要: The present invention provides a chimeric cytokine receptor comprising a cytokine receptor endodomain which comprises a first chain and a second chain, wherein the first and/or second chain of the cytokine-receptor endodomain is/are truncated. The invention also provides cells comprising such a chimeric cytokine receptor, optionally in combination with a chimeric antigen receptor (CAR) and their use in the treatment of diseases such as cancer.
-
-
-
-
-
-
-
-
-